Human Anti-CD50 / ICAM-3 Antibody Product Attributes
Species: Human
Tested Applications: Bioactive, Flow Cytometry, Immunofluorescence, Immunohistochemistry (IHC).
Application Notes: Blocks binding of CD11a (LFA-1) to CD50 (ICAM-3), Flow Cytometry (0.5-1ug of antibody/million cells in 0.1ml), Immunofluorescence (0.5-1ug of antibody/ml), Immunohistochemistry (IHC) (Formalin-fixed) (0.5-1ug of antibody/ml for 30 minutes at RT)
Clonality: Monoclonal
Anti-CD50 / ICAM-3 Antibody Clone: 186-2G9
Clone 186-2G9 Host and Isotype: Mouse IgG2b kappa
Anti-Human CD50 / ICAM-3 Positive Control Sample: HL-60 or THP-1 cells. Lymph node, tonsil
Cellular Localization of Antibody <186-2G9 Staining: Cell surface
Buffer and Stabilizer: 10mM PBS with 0.05% BSA & 0.05% azide.
Antibody Concentration: 200ug/ml
Antibody Purification Method:Protein A/G Purified
Immunogen: Stimulated human leukocytes
Storage Conditions: Store at 2 to 8° C (refrigerate). Stable for 24 months when properly stored.
CD50 / ICAM-3 Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Anti-ICAM3 antibody staining is expected to be primarily localized to the mitochondria, nuclear membrane and nucleus.Observed Antibody Staining Data By Tissue Type:
Variations in CD50 / ICAM-3 antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in cells in the red pulp in spleen, cells in the white pulp in spleen, epidermal cells in the skin, germinal center cells in the tonsil, hematopoietic cells in the bone marrow, lymphoid tissue in appendix and non-germinal center cells in the lymph node and tonsil. More moderate antibody staining intensity was present in cells in the red pulp in spleen, cells in the white pulp in spleen, epidermal cells in the skin, germinal center cells in the tonsil, hematopoietic cells in the bone marrow, lymphoid tissue in appendix and non-germinal center cells in the lymph node and tonsil. Low, but measureable presence of CD50 / ICAM-3 could be seen in. We were unable to detect CD50 / ICAM-3 in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of CD50 / ICAM-3 expression as measured by anti-CD50 / ICAM-3 antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | - | - | - | - | - | - | - | - | - | +++ | - | - | - | - | - | - | - | - | - | - |
| ICAM3 Variability | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | ++ |
Limitations and Warranty
enQuire Bio's CD50 / ICAM-3 Anti-Human Monoclonal is available for Research Use Only. This antibody is guaranteed to work for a period of two years when properly stored.
There are no reviews yet.